clinical trial · NCT06294912
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Merck Sharp & Dohme LLC·phase1·completed·n = 16
MalariaPlasmodium falciparumMK-7602Artemether/lumefantrinePrimaquineArtesunateAtovaquone/proguanil
brief summary
The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.
started
Apr 18, 2024
primary completion
Jan 6, 2025
completion
Jan 6, 2025
last updated
Jan 13, 2025
official title
A Controlled Human Malaria Infection Study to Evaluate the Antimalarial Activity of MK-7602 Against Plasmodium Falciparum Blood Stage Infection in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol